Previous 10 | Next 10 |
Boca Raton, Florida, June 22, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announces the issuance ...
A group of low cap biotechs are leading a selloff among Alzheimer’s drug developers after Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced on Thursday that their experimental drug for the memory robbing disease did not meet key goals in a mid-stage trial. Developed by the fellow Swiss biote...
In pre-clinical models of trastuzumab resistant MUC4 HER2+ breast cancer, treatment with INB03™ decreases MUC4 expression, reverses resistance to trastuzumab based therapies, and promotes an immunologically active TME. Data presented at noon today at the HER2 Targeted Thera...
INmune Bio's XPro is probably the most-promising drug candidate in the history of neurodegenerative diseases. INMB’s share price just dropped at an all-time low due to a US-related clinical hold for XPro. Trials are still ongoing in Australia, and I expect the hold on the U...
Gainers: Better Therapeutics (BTTX) +26%. America's Car-Mart (CRMT) +25%. GeoVax Labs (GOVX) +17%. Platinum Group Metals (PLG) +17%. Zentek (ZTEK) +16%. China Liberal Education Holdings (CLEU) +13%. Charge Enterprises (CRGE) +13%. Citi Trends (CTRN) +13%. Cango (CANG) +13%. Losers: Snap (SNAP...
Uber (NYSE:UBER) was among the standout decliners on an overall weak day for the market, dropping in Tuesday's midday trading following a cautious analyst comment. INmune Bio (INMB) also suffered an intraday slide, losing around a quarter of its value on a regulatory setback. Meanwhile,...
Shares of INmune Bio (NASDAQ:INMB) are down 22% in Tuesday morning trading following the company's announcement after Monday's closing bell that the U.S. FDA has placed on hold starting a phase 2 trial Alzheimer's disease candidate XPro1595. The FDA also requested additional details...
Gainers: Allarity Therapeutics (ALLR) +13%. Better Therapeutics (BTTX) +19%. GeoVax Labs GOVX +10%. Insulet PODD +7%. MDxHealth (MDXH) +5%. Losers: INmune Bio (INMB) -29%. Liquidia (LQDA) -21%. TherapeuticsMD (TXMD) -19%. Aethlon Medical (AEMD) -14%....
INmune Bio (NASDAQ:INMB) on Monday said the U.S. Food and Drug Administration (FDA) in May placed the company's new drug application to start its phase 2 trial of its tumor necrosis factor inhibitor XPro1595 in Alzheimer's Disease patients on hold. INMB stock falls 11.7% after hours...
BOCA RATON, FL., May 23, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that on May ...
News, Short Squeeze, Breakout and More Instantly...
The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint. The interim analysis, performed by a third-party, demonstrated no need to change trial design or size. BOCA RATON, Fla., June 27, 2024 (GLOBE N...
2024-06-12 14:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Boca Raton, Florida, May 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual r...